ERBB2 and non-small cell lung carcinoma: The overall response rate (ORR) to platinum-based chemotherapy was around 43%, with a median progression-free-survival (mPFS) of around 6 months; in particular, the use of pemetrexed increased the ORRs up to 30–56% in previously untreated patients with HER2-alterated NSCLC [26,27,28].